文献速递其他结缔组织病

乌司奴单抗治疗对一种或多种标准治疗应答不充分的日本活动性多发性肌炎和皮肌炎患者的3期、多中心、随机、双盲、安慰剂对照、平行组研究

Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
PubMed 文献 · RMD Open · 2023-01-01

在51例对一种或多种标准治疗应答不充分的日本活动性多发性肌炎/皮肌炎成人患者中,按1:1随机接受乌司奴单抗(n=25)或安慰剂(n=26)。第24周达到IMACS TIS最小改善(≥20)的比例为乌司奴单抗64.0% vs 安慰剂61.5%(p=0.94),无统计学显著差异;乌司奴单抗安全且耐受性良好,但主要疗效终点未达到。

要点

  • 第24周IMACS TIS最小改善(≥20)比例:乌司奴单抗组64.0% vs 安慰剂组61.5%(p=0.94),无统计学显著差异。
  • 乌司奴单抗在活动性多发性肌炎/皮肌炎日本成人中安全且耐受性良好。
  • 基于第24周主要分析,乌司奴单抗未达到主要疗效终点。

核心结论

  • 乌司奴单抗安全且耐受性良好,但基于本研究的第24周主要分析,在活动性多发性肌炎/皮肌炎日本成人参与者中未达到主要疗效终点。

研究设计与样本

  • 3期、多中心、随机、双盲、安慰剂对照、平行组研究,纳入51例对一种或多种标准治疗应答不充分的日本活动性多发性肌炎/皮肌炎成人患者,按1:1随机接受乌司奴单抗(n=25)或安慰剂(n=26)。
  • 第0周按体重范围静脉给予乌司奴单抗6 mg/kg或安慰剂,自第8周至第24周每8周皮下给予乌司奴单抗或安慰剂90 mg。
  • 第24周安慰剂组交叉接受按体重范围静脉给予乌司奴单抗,此后所有参与者接受/将接受乌司奴单抗90 mg每8周皮下给药(第32周至第72周)。

主要发现

  • 第24周达到IMACS TIS最小改善(≥20)的参与者比例:乌司奴单抗组64.0% vs 安慰剂组61.5%(p=0.94),基于主要终点分析的主要估计目标,两组间无统计学显著差异。

关键数值与推荐

  • 主要疗效终点为第24周达到国际肌炎评估和临床研究总改善评分(IMACS TIS)最小改善(≥20)的参与者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of ustekinumab (UST) in a multicentre, randomised, double-blind, placebo-controlled trial in adult Japanese patients with active polymyositis (PM) and dermatomyositis (DM). METHODS: Fifty-one Japanese adults diagnosed with active PM/DM who did not respond adequately to one or more standard-of-care treatments were randomised 1:1 to receive UST (n=25) or placebo (n=26). Participants received body weight-range based intravenous administration of UST (6 mg/kg) or placebo at week 0 followed by 90 mg subcutaneous (SC) administration of UST or placebo every 8 weeks from week 8 to week 24. At week 24, placebo group crossed over to receive body weight-range based intravenous administration of UST, and thereafter, all participants received/were to receive SC administration of UST 90 mg every 8 weeks (week 32 through to week 72). The primary efficacy endpoint was the proportion of participants who achieved minimal improvement (≥20) in the International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS TIS) at week 24. RESULTS: No statistically significant difference was seen in the proportion of participants who achieved minimal improvement (≥20) in IMACS TIS at week 24 between the treatment groups (UST 64.0% vs placebo 61.5%, p=0.94) based on the primary estimand of the primary endpoint analysis. CONCLUSIONS: UST was safe and well tolerated but did not meet the primary efficacy endpoint in adult Japanese participants with active PM/DM based on the primary analysis at week 24 in the study. TRIAL REGISTRATION NUMBER: NCT03981744.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kawahata K, Ishii T, Gono T, et al. Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments. RMD Open. 2023. PMID: 37652554. doi:10.1136/rmdopen-2023-003268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。